SLSSELLAS Life Sciences Group, Inc.vs its industry peers
A metric-by-metric comparison of SELLAS Life Sciences Group, Inc. against SPDR S&P Biotech ETF holdings — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SLSThis | $2.3B#15 | — | 16.6x#10 | — | -100.0%#9 | 13.0%#6 | — | -19.5%#9 | — | — | — | — |
| MRNA | $57.4B#1 | — | 8.5x#7 | 29.5x#3 | -39.9%#7 | 20.8%#5 | -158.1%#4 | -41.7%#12 | -54.6%#4 | — | — | — |
| TWST | $8.6B#8 | — | 19.4x#12 | 23.0x#2 | 20.3%#5 | 62.8%#1 | -36.2%#2 | -17.4%#8 | -41.4%#3 | — | — | — |
| ORKA | $6.1B#11 | — | 5.5x#3 | — | — | -25.9%#8 | — | -9.5%#4 | — | — | — | — |
| KYMR | $9.4B#5 | — | 6.2x#4 | 239.9x#6 | -16.7%#6 | 39.1%#2 | -891.1%#6 | 20.6%#1 | — | — | — | — |
| VKTX | $3.5B#14 | — | 8.6x#8 | — | — | -227.1%#15 | — | -88.1%#14 | — | — | — | — |
| PRAX | $8.7B#7 | — | 6.5x#6 | — | -100.0%#9 | -65.6%#11 | — | -22.6%#10 | — | — | — | — |
| ERAS | $5.7B#13 | — | 15.7x#9 | — | — | 23.0%#4 | — | -34.4%#11 | — | — | — | — |
| RVMD | $43.9B#3 | — | 16.9x#11 | — | — | -88.5%#13 | — | -43.4%#13 | — | — | — | — |
| RYTM | $6.7B#9 | — | 64.7x#14 | 35.1x#4 | 45.8%#3 | 24.6%#3 | -101.2%#3 | -0.2%#3 | -133.8%#5 | — | — | — |
| CGON | $6.4B#10 | — | 6.3x#5 | 1592.7x#7 | 254.7%#2 | -82.9%#12 | -4722.1%#7 | -15.6%#7 | -18.8%#2 | — | — | — |
| PCVX | $8.8B#6 | — | 3.2x#1 | — | — | -65.2%#10 | — | -0.0%#2 | — | — | — | — |
| DNTH | $5.9B#12 | — | 5.0x#2 | 2876.5x#8 | -67.3%#8 | -91.1%#14 | -8739.3%#8 | -13.9%#6 | — | — | — | — |
| CYTK | $9.6B#4 | — | — | 109.5x#5 | 376.6%#1 | -33.2%#9 | -695.4%#5 | — | — | — | — | — |
| NTRA | $50.6B#2 | — | 27.8x#13 | 21.9x#1 | 35.9%#4 | -9.3%#7 | -13.4%#1 | -11.4%#5 | -18.0%#1 | — | 103.6%#1 | — |
Peer set: top holdings of XBI (SPDR S&P Biotech ETF), the indexed fund holding this stock at its highest weight — a fund manager's grouping, not Tickwind's judgement. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-15.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice